nach oben

Erschienen in:

01.03.2020 | Clinical study

Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity

Erschienen in: Reactions Weekly | Ausgabe 1/2020

Einloggen, um Zugang zu erhalten

Excerpt

In women with metastatic human epidermal growth factor receptor-2 positive (HER2+) breast cancer, prolonged treatment with trastuzumab appears to be associated with high rates of cardiotoxicity, according to study results reported in the American Journal of Cardiology, but rates of cardiology referral and cardiac treatment were low, "reflecting a potential cardiac care gap". …

Calvillo-Arguelles O, et al. Trastuzumab-Related Cardiotoxicity and Cardiac Care in Patients With HER2 Positive Metastatic Breast Cancer. American Journal of Cardiology : 27 Jan 2020. Available from: URL: http://doi.org/10.1016/j.amjcard.2020.01.029

Titel: Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity
Publikationsdatum: 01.03.2020
Verlag: Springer International Publishing
Erschienen in: Reactions Weekly / Ausgabe 1/2020
Print ISSN: 0114-9954
Elektronische ISSN: 1179-2051
DOI: https://doi.org/10.1007/s40278-020-75808-7

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Trastuzumab in metastatic HER2+ breast cancer: cardiotoxicity

Excerpt

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2020

Antineoplastics

Epinephrine/norepinephrine/vasopressin

Bupropion

Erlotinib

Alemtuzumab/pentostatin/venetoclax

Methylprednisolone/prednisolone